Diarrhoea is the most frequently gastrointestinal irAE in patients receiving ipilimumab (34%), a frequency higher than that after anti–PD-1 monotherapy (21%) (Wolchok et al., 2017). This evidence concerns the gene RPL17 and Diarrhea.